Updates are available Correction dated 2025-08-04
Click to view Correction: https://doi.org/10.1038/s41591-025-03896-0
-
Authors
Borgers, Jessica S. W. https://orcid.org/0000-0002-6478-7821
Lenkala, Divya
Kohler, Victoria
Jackson, Emily K. https://orcid.org/0000-0002-2972-4139
Linssen, Matthijs D. https://orcid.org/0000-0002-0492-066X
Hymson, Sebastian https://orcid.org/0009-0001-1823-9680
McCarthy, Brian
O’Reilly Cosgrove, Elizabeth
Balogh, Kristen N. https://orcid.org/0000-0002-8746-745X
Esaulova, Ekaterina
Starr, Kimberly
Ware, Yvonne https://orcid.org/0009-0007-7911-0403
Klobuch, Sebastian https://orcid.org/0000-0003-1364-0763
Sciuto, Tracey
Chen, Xi
Mahimkar, Gauri
Sheen, Joong Hyuk F. https://orcid.org/0000-0002-1855-0268
Ramesh, Suchitra
Wilgenhof, Sofie https://orcid.org/0000-0002-3309-4555
van Thienen, Johannes V.
Scheiner, Karina C.
Jedema, Inge https://orcid.org/0000-0001-9042-6459
Rooney, Michael
Dong, Jesse Z.
Srouji, John R.
Juneja, Vikram R.
Arieta, Christina M.
Nuijen, Bastiaan
Gottstein, Claudia https://orcid.org/0009-0008-1117-8417
Finney, Olivia C. https://orcid.org/0000-0002-7952-9075
Manson, Kelledy
Nijenhuis, Cynthia M.
Gaynor, Richard B.
DeMario, Mark
Haanen, John B. https://orcid.org/0000-0001-5884-7704
van Buuren, Marit M. https://orcid.org/0000-0002-1615-1087
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 13 November 2024
First Online: 3 January 2025
Change Date: 4 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03896-0
Competing interests
: J.S.W.B., J.V.v.T., S.K., S.W. and I.J. declare no competing interests. D.L., V.K., E.K.J., S.H., E.O.C., K.N.B., E.E., K.S., Y.W., T.S., X.C., G.M., J.H.F.S., S.R., M.R., J.Z.D., J.R.S., V.R.J., C.M.A., C.G., O.C.F., K.M., R.B.G., M.D.M. and M.M.v.B. are employees of BioNTech US or BioNTech SE. B.M.C. is a former employee of BioNTech US. V.K., S.H., K.N.B., K.S., Y.W., X.C., S.R., J.R.S., V.R.J., C.M.A, O.C.F., K.M., R.B.G., M.D.M. and M.M.v.B. own stock in BioNTech. C.M.N., B.N., K.C.S. and M.D.L. are contractors for BioNTech US for manufacture of the BNT221 drug product. M.M.v.B., D.L., C.M.A., J.B.H. and M.D.M. are inventors on patent applications that cover part of this article. J.B.H. received grant or research support from BioNTech US, Bristol Myers Squibb, Novartis AG, Amgen, Sastra Cell Therapy and Asher Bio. BioNTech’s role in this study is disclosed in the author contributions; none of the other organizations had a role in the study or publication. J.B.H. discloses ownership interest in Neogene Therapeutics. J.B.H. has an advisory role for Agenus, AstraZeneca, Bristol Myers Squibb, CureVac, GSK, Imcyse, Iovance Bio, Immunocore, Ipsen, Merck Serono, Merck Sharp & Dohme, Molecular Partners, Novartis, Orgenesis, Pfizer, Roche/Genentech, Sanofi and Third Rock Ventures and is a scientific advisory board (SAB) member at Achilles Tx, BioNTech US, Instil Bio, T-Knife, Neogene Therapeutics (AstraZeneca) and Sastra Cell Therapy. R.B.G. is on the Board of Directors for Alkermes and Zai Lab and is a member of the SAB for Leap Therapeutics.
